Target intelligence / Profile preview

Potassium voltage-gated channel subfamily C member 1 (Kv3.1) and Potassium voltage-gated channel subfamily C member 2 (Kv3.2) (Kv3.1 (for KCNC1), Kv3.2 (for KCNC2))

Target
Kv3.1 (for KCNC1), Kv3.2 (for KCNC2)
Molecular classification
Ion channel, Voltage-gated potassium channel
01

Overview

Kv3.1 (Potassium voltage-gated channel subfamily C member 1) and Kv3.2 (Potassium voltage-gated channel subfamily C member 2) are high-threshold, voltage-gated potassium channels that play a crucial role in enabling rapid neuronal firing, particularly in fast-spiking interneurons in the cortex, hippocampus, and cerebellum[2][3][5]. Their tetrameric channel structure allows for very fast activation and deactivation, supporting high-frequency neuronal activity essential for precise timing in neural circuits involved in movement, sensory processing, and cognition[2][5][7]. Mutations in either KCNC1 or KCNC2 disrupt this critical function, which can result in diseases such as epilepsy, ataxia, and developmental disabilities[3][4][6]. Kv3.1 and Kv3.2 channels are under investigation as targets for new therapeutic agents, especially for genetic and acquired epilepsies and neuropsychiatric disorders[6].

Other names
KCNC1Kv3.1aKv3.1bKCNC2Kv3.2aKv3.2bKv3.2cKv3.2d
02

Mechanism of action

Activation (potentiation) of channel to restore or enhance repolarization Inhibition to reduce neuronal excitability (potential anti-epileptic strategy)

03

Biological functions

Rapid neuronal repolarizationHigh-frequency action potential firingRegulation of excitability in fast-spiking interneuronsNeurotransmitter release
04

Disease associations

EpilepsyDevelopmental delay and intellectual disabilityAtaxiaNeurodegenerative diseasePsychiatric disorders
05

Safety considerations

Off-target effects altering normal excitability of neuronsPotential for pro-convulsant or ataxic effects with channel inhibition or dysfunctionUnknown long-term effects of Kv3 modulation
06

Interacting drugs

RE01 (Kv3.1 activator, preclinical)

2 more in the full profile.

07

Biomarkers

Genetic variants/mutations in KCNC1 or KCNC2 for disease diagnosis (e.g., myoclonus epilepsy and ataxia)Functional channel activity in patient-derived neurons (iPSC models)

Beyond the preview

Go deeper on Potassium voltage-gated channel subfamily C member 1 (Kv3.1) and Potassium voltage-gated channel subfamily C member 2 (Kv3.2) (Kv3.1 (for KCNC1), Kv3.2 (for KCNC2)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Potassium voltage-gated channel subfamily C member 1 (Kv3.1) and Potassium voltage-gated channel subfamily C member 2 (Kv3.2) (Kv3.1 (for KCNC1), Kv3.2 (for KCNC2)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call